JOURNEY MEDICAL CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.4 USD | -2.86% |
|
-2.30% | -40.97% |
| 03-21 | Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024 | |
| 03-21 | Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 58.01M 4.64B | Sales 2025 * | 82.04M 6.57B | Capitalization | 67.77M 5.43B |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -1.2B | Net income 2025 * | -4M -320M | EV / Sales 2024 * | 1.17 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.83 x |
| P/E ratio 2024 * |
-4.59
x | P/E ratio 2025 * |
-17
x | Employees | 41 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Journey Medical Corporation
More recommendations
More press releases
| 1 day | -2.86% | ||
| 1 week | -2.30% | ||
| Current month | -7.61% | ||
| 1 month | -7.86% | ||
| 3 months | -32.54% | ||
| 6 months | +1.49% | ||
| Current year | -40.97% |
1 week
3.31
3.63
1 month
3.204.64
Current year
2.856.15
1 year
1.028.11
3 years
1.0210.20
5 years
1.0210.20
10 years
1.0210.20
| Managers | Title | Age | Since |
|---|---|---|---|
Claude Maraoui
FOU | Founder | 57 | 30/09/14 |
Joseph Benesch
DFI | Director of Finance/CFO | 57 | 31/10/21 |
| Chief Tech/Sci/R&D Officer | - | 31/08/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | - | |
Neil Herskowitz
BRD | Director/Board Member | 67 | - |
Miranda Toledano
BRD | Director/Board Member | 47 | 30/04/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.4 | -2.86% | 64,845 |
| 25/04/24 | 3.5 | +2.94% | 46,341 |
| 24/04/24 | 3.4 | -3.95% | 60,474 |
| 23/04/24 | 3.54 | 0.00% | 75,360 |
| 22/04/24 | 3.54 | +1.72% | 37,549 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
Sector
Pharmaceuticals
Calendar
01/05/2024
- Planet MicroCap Showcase
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.4
USD
Average target price
8.25
USD
Spread / Average Target
+142.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.97% | 67.77M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DERM Stock
